Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits
Frazer I. Heinis, … , Matthew Wheelwright, Joseph M. Metzger
Frazer I. Heinis, … , Matthew Wheelwright, Joseph M. Metzger
Published February 8, 2024
Citation Information: JCI Insight. 2024;9(6):e163334. https://doi.org/10.1172/jci.insight.163334.
View: Text | PDF
Research Article Cardiology

Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits

  • Text
  • PDF
Abstract

Severe dysfunction in cardiac muscle intracellular Ca2+ handling is a common pathway underlying heart failure. Here we used an inducible genetic model of severe Ca2+ cycling dysfunction by the targeted temporal gene ablation of the cardiac Ca2+ ATPase, SERCA2, in otherwise normal adult mice. In this model, in vivo heart performance was minimally affected initially, even though Serca2a protein was markedly reduced. The mechanism underlying the sustained in vivo heart performance in the weeks prior to complete heart pump failure and death is not clear and is important to understand. Studies were primarily focused on understanding how in vivo diastolic function could be relatively normal under conditions of marked Serca2a deficiency. Interestingly, data show increased cardiac troponin I (cTnI) serine 23/24 phosphorylation content in hearts upon Serca2a ablation in vivo. We report that hearts isolated from the Serca2-deficient mice retained near normal heart pump functional responses to β-adrenergic stimulation. Unexpectedly, using genetic complementation models, in concert with inducible Serca2 ablation, data show that Serca2a-deficient hearts that also lacked the central β-adrenergic signaling–dependent Serca2a negative regulator, phospholamban (PLN), had severe diastolic dysfunction that could still be corrected by β-adrenergic stimulation. Notably, integrating a serines 23/24–to–alanine PKA-refractory sarcomere incorporated cTnI molecular switch complex in mice deficient in Serca2 showed blunting of β-adrenergic stimulation–mediated enhanced diastolic heart performance. Taken together, these data provide evidence of a compensatory regulatory role of the myofilaments as a critical physiological bridging mechanism to aid in preserving heart diastolic performance in failing hearts with severe Ca2+ handling deficits.

Authors

Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger

×

Figure 2

Effects of CPA chemical inhibition of the Serca2a ATPase in hearts after Serca2 gene ablation.

Options: View larger image (or click on image) Download as PowerPoint
Effects of CPA chemical inhibition of the Serca2a ATPase in hearts after...
KO data are at 2–6 weeks after gene ablation (Figure 1A). (A and B) Representative LV pressure traces from FL (A) and KO (B) hearts perfused with Krebs (gray trace) and 5 μM CPA (black trace). In each experiment, pacing was increased stepwise from 7 Hz to 12 Hz and then back to baseline 7 Hz, as in Supplemental Figure 2. (C) Representative traces of LV pressure from FL and SERCA2-KO hearts perfused with Krebs (solid line) and 5 μM CPA (dashed line). (D) Time from peak pressure to 50% decay during pacing steps from 7 to 12 Hz in FL and KO hearts. T50Relax was increased in FL hearts following CPA perfusion, but it was not significantly changed in KO hearts. Groups compared using 2-way ANOVA with Bonferroni post hoc tests. (E) Summary of change (Δ) in LVDP between baseline Krebs and 5 μM CPA perfusion. ***P < 0.0001 by 2-tailed Student’s t test. (F) Change in LVDP between baseline and CPA perfusion expressed as a fraction of baseline LVDP. ***P < 0.0001 by 2-tailed Student’s t test. (G) Full-duration at half-maximum (FDHM), the sum of T50Rise and T50Relax representing the duration of the active state of contraction, for FL and KO hearts at 7 Hz. FDHM of KO hearts is not affected by CPA treatment. n = 6 FL, 7 KO.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts